Tami T. Martin
Net Worth
Last updated:
What is Tami T. Martin net worth?
The estimated net worth of Ms. Tami T. Martin is at least $10,713,516 as of 30 Aug 2023. She owns shares worth $3,509,701 as insider, has earned $766,215 from insider trading and has received compensation worth at least $6,437,600 in Supernus Pharmaceuticals, Inc..
What is the salary of Tami T. Martin?
Ms. Tami T. Martin salary is $495,200 per year as Senior Vice President of Regulatory Affairs in Supernus Pharmaceuticals, Inc..
How old is Tami T. Martin?
Ms. Tami T. Martin is 70 years old, born in 1955.
What stocks does Tami T. Martin currently own?
As insider, Ms. Tami T. Martin owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. (SUPN) | Senior Vice President of Regulatory Affairs | 85,249 | $41.17 | $3,509,701 |
What does Supernus Pharmaceuticals, Inc. do?
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.
Tami T. Martin insider trading
Supernus Pharmaceuticals, Inc.
Ms. Tami T. Martin has made 6 insider trades between 2012-2023, according to the Form 4 filled with the SEC.
The largest trade she's ever made was exercising 48,125 units of SUPN stock on 12 Dec 2012. As of 30 Aug 2023 she still owns at least 85,249 units of SUPN stock.